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Neurological deterioration in young adults
with phenylketonuria
SIR,-Since diet treatment began for phenylketonuria (PKU) 30
years ago several caveats have emerged: (a) neonatal diagnosis is
essential and is the basis of screening programmes, though this time
frame for diagnosis is controversial; (b) excessive dietary restriction
of essential aminoacids is harmful to infant growth and
development; and (c) "IQ deterioration" has followed diet
termination before 10 years of age in some studies.2 Dr Thompson
and colleagues (Sept 8, p 602) extend the concern over diet
termination leading to neurological deterioration in young adults
with PKU. These caveats, however, lack scientific support. There
are no case-control cohort data, such as meta-analyses, that examine
hypotheses affecting PKU health-care attitudes; and ethical
concerns prevent scientific cohort studies in infants and children.
Nonetheless, this model of a treatable, rare metabolic disorder that
is limited in clinical neuroepidemiological information examined by
cost-effective analyses does influence national child health policies.
While the neurological symptoms observed by Thompson et al
could be a sign of central nervous system (CNS) deterioration,
independent neurological progression from previous brain insult or
the appearance of another concurrent or contiguous disease should
be considered. In the absence of prevalence data and case-control
investigations conflicting viewpoints are not uncommon in PKU
management. Specific CNS molecular mechanisms have not been
established for this metabolic encephalopathy. There are, however,
many excellent scientific observations, such as those on movement
disorders, that expand speculation about aetiology. Disordered
metabolism of myelin must now be supplemented with the evidence
of neurochemical perturbations of neurotransmitters, co-factors,
the blood-brain-barrier, and neurocellular development.
Histopathological studies on in-utero PKU fetal brain injury reveal
dendritic abnormalities with normal myelination.3 Brain ontogeny
and plasticity in the milieu of excitatory aminoacids suggest a
common ground between brain insults such as hypoxia-ischaemia
and metabolic disease.4
Thompson et al suggest diet termination as the most likely
explanation of the neurological symptoms. However, the infant
PKU brain, damaged by delayed treatment, may respond
differently to a recurrent biochemical insult. 3 of the 7 infants were
diagnosed and treated at ages of 15,18, and 24 months, well beyond
the average age of neonatal screening. 2 had infantile spasms, an
ominous sign of permanent brain injury from any origin. In our
25-year experience only babies missed by neonatal screening and
treated after 6 months of age acquire this disorder. In patients 1 and
3, with "poor growth", there could be a relation with nutritionally
deficient diets. Furthermore, patient 5, with dystonia without a
co-factor abnormality, resembles an adult dystonic patient with
biopterin deficiency.’ Patient 2, with pyramidal weakness and
unknown phenylalanine levels who had been "on diet" for 16 years
is clinically similar to the spasticity and parkinsonism described in
PKU at different ages. Idiopathic dystonia responds to pterin
treatment, as do patients with co-factor deficiency.
Dystonia is a regional neostriatal disorder, often without
neuropathological abnormalities such as demyelination but with
several monoaminergic abnormalities. Dystonia is not an
uncommon idiopathic neurological symptom. Late-onset
progressive dystonia after neonatal hypoxic-ischaemic brain
damage is well known and could include the brain damage of
neonatal metabolic disorders. Late-onset pterin-deficiency dystonia
developing in childhood after screening in infancy responds to
biopterin treatment but not to diet. Dystonia and parkinsonism in
ptenn-deficient variant PKU may appear in infancy.7.8
PKU infants and children while under biochemical control may
marufest major second disorders such as microcephaly, motoneuron
diseases, and ataxia telangiectasia; minor structural abnormalities
are also observed in metabolic disorders. The fmdings in late-
treated adults are difficult to differentiate from multiple sclerosis.9
EBen phenylalanine in the dietary sweetener aspartame has been
mplicated in neurological symptoms10 in PKU.
Our neurological study consists of a cohort of 309 newborn babies
with PKU detected in 3 milhon births, representing total
ascertainment in a population of 10 million people between 1965
and 1990. PKU adults identified before and after this period are
under long-term neurological observation; only the 1 infant with
variant PKU is dystonic. Caveats about dietary treatment in PKU
still await pathophysiological and neuroepidemiological data.
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Phyllanthus amarus and hepatitis B
SIR,-Dr Leelarasamee and colleagues (June 30, p 1600) report the
failure of Phyllanthus amarus to eradicate hepatitis B surface antigen
from symptomless carriers. Our Lancet paper1 on the effects of
P amarus in chronic carriers of hepatitis B virus (HBV) drew
comments in the joumaP and via personal communication. The
main criticisms of our preliminary studyl were that HBV-DNA
estimations were not done in the pretreatment and post treatment
samples of the cleared and refractory carriers; that HBeAg to
anti-HBe seroconversion was not fully evaluated; and that long-
term carriers (ie, those who carry HBsAg for a year or more) were
not studied.
With these criticisms in mind we did an open trial in 1989-90 on
28 symptomless chronic HBV carriers known to have carried
HBsAg for at least a year and up to 5 years. They were treated with
250 mg capsules of P amarus thrice daily for 3 months. Serum was
obtained before treatment, once a month during treatment, and
after treatment up to one year of follow-up. Sera were screened for
HBV serological markers (HBsAg seroconversion, anti-HBc IgM,
HBe seroconversion) with Organon ELISA kits. HBV-DNA
analysis was done by dot-blot hybridisation,3 the probe being kindly
provided by Dr Stephen Locamini (Fairfield Hospital, Melbourne,
Australia).
Analysis of the data after the treatment period revealed loss of
HBsAg in 20% of carriers, in contrast to 59% in our earlier study /
All those who have cleared HBsAg were HBeAg negative carriers.
Of the 4 HBsAg cleared cases, 3 seroconverted to anti-HBs. None
seroconverted from HBeAg positivity to anti-HBe positivity (table).
On analysis of HBV-DNA, 15 showed pretreatment positivity (8/11
HBeAg positive, 7/9 HBeAg negative). After treatment with
P amarus in 2 out of 8 HBeAg positive cases and 4 out of 7 in the
HBeAg negative group, HBV-DNA was not detectable in post
treatment sera. HBeAg positive carriers seem to go through a
sequential pattern of HBe seroconversion followed by a reduction in
HBV-DNA levels during treatment before HBV-DNA becomes
undetectable. Long-term P amarus treatment of HBeAg positive
carriers for at least 6 months at a dose of 500 mg thrice daily might
yield better results.
P amarus is being studied in a multi centre trial in HBV carriers in
New Zealand, Vanavatu, Australia, Egypt, Singapore, China, the
